BioXcel Therapeutics Inc
BTAI2.279USD
+0.909+66.32%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
12.46MCap. mercado
PérdidaP/E TTM
Más Datos de BioXcel Therapeutics Inc Compañía
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Información de la empresa
Símbolo de cotizaciónBTAI
Nombre de la empresaBioXcel Therapeutics Inc
Fecha de salida a bolsaMar 08, 2018
Director ejecutivoDr. Vimal Mehta, Ph.D.
Número de empleados37
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 08
Dirección555 Long Wharf Dr
CiudadNEW HAVEN
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal06511-6107
Teléfono12036438060
Sitio Webhttps://www.bioxceltherapeutics.com/
Símbolo de cotizaciónBTAI
Fecha de salida a bolsaMar 08, 2018
Director ejecutivoDr. Vimal Mehta, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Vimal Mehta, Ph.D.
Dr. Vimal Mehta, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
19.80K
+373.89%
Mr. David J. Mack
Mr. David J. Mack
Independent Director
Independent Director
18.62K
+10.00%
Dr. Michal Votruba, M.D., Ph.D.
Dr. Michal Votruba, M.D., Ph.D.
Independent Director
Independent Director
11.52K
--
Dr. Peter Mueller, Ph.D.
Dr. Peter Mueller, Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
7.49K
-42.90%
Mr. Javier Rodriguez
Mr. Javier Rodriguez
Senior Vice President, Chief Legal Officer, Corporate Secretary
Senior Vice President, Chief Legal Officer, Corporate Secretary
6.66K
+301.39%
Mr. Richard I. Steinhart
Mr. Richard I. Steinhart
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
6.44K
+346.98%
Mr. Erik Kopp
Mr. Erik Kopp
Investor Relations
Investor Relations
--
--
DR. Frank D. Yocca ,Ph.D.
DR. Frank D. Yocca ,Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Dr. Rajiv Patni, M.D.
Dr. Rajiv Patni, M.D.
Independent Director
Independent Director
--
--
Ms. June Bray
Ms. June Bray
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Vimal Mehta, Ph.D.
Dr. Vimal Mehta, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
19.80K
+373.89%
Mr. David J. Mack
Mr. David J. Mack
Independent Director
Independent Director
18.62K
+10.00%
Dr. Michal Votruba, M.D., Ph.D.
Dr. Michal Votruba, M.D., Ph.D.
Independent Director
Independent Director
11.52K
--
Dr. Peter Mueller, Ph.D.
Dr. Peter Mueller, Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
7.49K
-42.90%
Mr. Javier Rodriguez
Mr. Javier Rodriguez
Senior Vice President, Chief Legal Officer, Corporate Secretary
Senior Vice President, Chief Legal Officer, Corporate Secretary
6.66K
+301.39%
Mr. Richard I. Steinhart
Mr. Richard I. Steinhart
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
6.44K
+346.98%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: jue., 24 de jul
Actualizado: jue., 24 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Bioxcel Corp
7.93%
Armistice Capital LLC
4.76%
Murchinson Ltd.
2.25%
UBS Financial Services, Inc.
1.68%
Goldman Sachs & Company, Inc.
0.41%
Other
82.97%
Accionistas
Accionistas
Proporción
Bioxcel Corp
7.93%
Armistice Capital LLC
4.76%
Murchinson Ltd.
2.25%
UBS Financial Services, Inc.
1.68%
Goldman Sachs & Company, Inc.
0.41%
Other
82.97%
Tipos de accionistas
Accionistas
Proporción
Corporation
7.93%
Hedge Fund
4.76%
Investment Advisor
2.76%
Investment Advisor/Hedge Fund
2.62%
Individual Investor
1.28%
Research Firm
0.89%
Other
79.75%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
225
1.20M
19.77%
-199.41K
2025Q1
248
1.19M
19.87%
-219.94K
2024Q4
260
1.00M
33.25%
-269.93K
2024Q3
269
724.21K
25.25%
-802.39K
2024Q2
282
1.14M
44.29%
-598.60K
2024Q1
282
1.17M
59.63%
-354.60K
2023Q4
282
1.17M
63.22%
-360.50K
2023Q3
290
1.23M
67.44%
-639.74K
2023Q2
289
1.71M
93.56%
-204.68K
2023Q1
297
1.69M
93.06%
-56.17K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Bioxcel Corp
480.34K
7.93%
-53.83K
-10.08%
Jun 06, 2024
Armistice Capital LLC
288.13K
4.76%
-24.20K
-7.75%
Mar 31, 2025
Murchinson Ltd.
136.08K
2.25%
+136.08K
--
Mar 31, 2025
UBS Financial Services, Inc.
101.78K
1.68%
+21.97K
+27.53%
Mar 31, 2025
Goldman Sachs & Company, Inc.
24.79K
0.41%
+24.79K
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
22.87K
0.38%
-508.00
-2.17%
Mar 31, 2025
Geode Capital Management, L.L.C.
22.06K
0.36%
+2.56K
+13.15%
Mar 31, 2025
Mehta (Vimal)
4.18K
0.07%
+382.00
+10.06%
Jun 15, 2025
Beacon Pointe Advisors LLC
18.84K
0.31%
+18.84K
--
Mar 31, 2025
The Vanguard Group, Inc.
18.82K
0.31%
+18.82K
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
ProShares Hedge Replication ETF
0%
Schwab U.S. Small-Cap ETF
0%
iShares Neuroscience and Healthcare ETF
0%
ProShares UltraPro Russell2000
0%
Schwab U.S. Broad Market ETF
0%
iShares Micro-Cap ETF
0%
iShares Morningstar Small-Cap ETF
0%
Fidelity MSCI Health Care Index ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
WisdomTree Artificial Intelligence and Innov Fund
0%
Ver más
ProShares Hedge Replication ETF
Proporción0%
Schwab U.S. Small-Cap ETF
Proporción0%
iShares Neuroscience and Healthcare ETF
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
Schwab U.S. Broad Market ETF
Proporción0%
iShares Micro-Cap ETF
Proporción0%
iShares Morningstar Small-Cap ETF
Proporción0%
Fidelity MSCI Health Care Index ETF
Proporción0%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0%
WisdomTree Artificial Intelligence and Innov Fund
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
Fecha
Tipo
Relación
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
